Year: 2014
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Patients with mild cognitive impairment (MCI) have varying risks of progression to Alzheimer's disease (AD). OBJECTIVE: To test the utility of the relative abundances of blood plasma polypeptides for predicting the risk of AD progression. METHODS: 119 blood plasma samples of patients with MCI with different outcomes (stable MCI and progressive MCI) were analyzed by untargeted, label-free shotgun proteomics. Predictive biomarkers of progressive MCI were selected by multivariate analysis, followed by cross-validation of the predictive model. RESULTS: The best model demonstrated the accuracy of ca. 79% in predicting progressive MCI. Sex differences of the predictive biomarkers were also assessed. We have identified some sex-specific protein biomarkers, e.g., alpha-2-macrogloblin (A2M), which strongly correlates with female AD progression but not with males. CONCLUSION: Significant sex bias in AD-specific biomarkers underscores the necessity of selecting sex-balanced cohort in AD biomarker studies, or using sex-specific models. Blood protein biomarkers are found to be promising for predicting AD progression in clinical settings.
Source: Journal of Alzheimer s Disease
DOI: 10.3233/jad-132102
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W1588945080